Research notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

FY26: key beneficiary of the upcycle

Aeris Resources
3:27pm
August 28, 2026
The FY26 result beat expectations with EBITDA of $318m +77% yoy and +7% vs MorgansF/consensus and NPAT of $178m +295% and +11%. The audited result does not change our view given FY27 guidance was already flagged in August, and we remain positive on AIS' leverage to strong copper and gold prices across Tritton and Cracow. We maintain a BUY rating with a A$0.63ps target price (previously A$0.55).

Foothills of a multi-year upgrade cycle

Civmec
3:27pm
August 28, 2026
The FY26 result was robust, and the order book stands at $1.4bn which almost entirely de-risks FY27. Further tendering activity across a heavy pipeline of projects across resources and public infrastructure should ensure an even stronger FY28, positioning CVL for an upgrade cycle. Moreover, prospects of winning defence work continue to strengthen, for both naval shipbuilding and the construction of the defence precinct at Henderson. This comes as a free option. We lift FY27-28 EBITDA +7-8% and our target price to $2.40 (from $2.30). BUY.

FY26 result: The opportunities are still there

VEEM
3:27pm
August 28, 2026
VEE’s FY26 result was in line with expectations and management’s guidance provided in June. FY26 was a transitional year for VEE, with revenue declining 25% and underlying EBITDA falling 61%, reflecting a downturn in the global marine market that weighed on propulsion revenue along with materially lower gyro orders. Encouragingly, propulsion revenue recovered in late FY26 and demand is expected to strengthen further in FY27. Gyro revenue should also improve as the full Mark III range becomes available over the next few months. With Defence opportunities continuing to progress, we remain positive on VEE’s long-term outlook, although the timing of order flow can cause earnings volatility in the near term. SPECULATIVE BUY rating maintained.

FY26: The sun sets on the growth story

Clinuvel Pharmaceuticals
3:27pm
August 28, 2026
CUV's FY26 result was soft, delivering the first annual revenue decline in the company’s history. The bigger story, though, is the Board's open consideration of a full Nasdaq listing and an ASX delisting. We lower our EPP assumptions, which have taken a competitive hit. FY26 earnings were flattered by R&D timing that we expect to reverse in FY27, and the long-term case now rests almost entirely on December's Vitiligo top-line. A$252m cash is the floor. We move to a HOLD (from Speculative Buy), with a lower target price of A$10 (from A$13). Our bear case is ~$7 on a Vitiligo failure.

1H26: looking ahead to the Dec-Q

29 Metals
3:27pm
August 28, 2026
1H26 EBITDA of $30.5m beat MorgansF by +8% but was a 20% miss to consensus. Importantly, the balance sheet remains solid with $202m of liquidity. Golden Grove is now approaching an inflection point as 29M moves closer to Xantho Extended coming back online, along with new ore sources from Gossan Valley and Oizon in Dec-Q. We maintain a HOLD rating with a A$0.35ps target price (previously A$0.26).

FY26: Engine rebuilt, but not yet in gear

Mach7 Technologies
3:27pm
August 28, 2026
The market should be broadly comfortable with the result given recent trading updates, but new contract delivery remains the key requirement before investors are likely to begin marking the stock materially higher. Revenue and OPEX landed broadly in line with guidance, while the NPAT miss was driven by a A$1.9m restructuring charge and a weaker tax benefit rather than deterioration in the core subscription business. Moderate increase in target price due to model roll-forward, lower share count, and leaner-than-expected cost base. Our target price rises to A$0.48 (from A$0.44) and we retain our Buy recommendation. Upside potential to target presents an opportunity but needs new contract momentum to spark renewed interest.

GMV acceleration becoming noteworthy

Airtasker
3:27pm
August 28, 2026
Airtasker's (ART) FY26 result was broadly in line with our expectations. Group revenue grew ~10% on pcp to A$57.8m (marketplaces revenue ex-OneFlare +15.5% to A$52m), and its earlier stage offshore marketplaces (UK/US) showed accelerating momentum and strong topline growth (+55%/150% respectively). ART also announced media deals with OML and Nova, extending the brand investment runway (media inventory to deploy from FY27 now ~A$24m). We make several changes to our assumptions across the forecast period (details below). Our price target remains unchanged at A$0.47. We retain our BUY recommendation.

A tight run

ImpediMed
3:27pm
August 28, 2026
IPD posted FY26 results which were lower than our forecasts. IPD completed a $15m capital raise providing an opportunity to grow SOZO placements in the US. The cadence of growth needs to accelerate for IPD to achieve break-even. We have revised forecasts down with a resultant adjustment to our TP, now $0.009 (was $0.01). We move to a HOLD recommendation (from SPECULATIVE BUY) while we wait to see growth in the SOZO installed base.

A tale of two halves

Camplify Holdings
3:27pm
August 28, 2026
CHL’s FY26 result was largely pre-released. However, while bookings late in the year were clearly impacted by macro and geopolitical events (e.g. fuel security concerns), the cost-out achieved in a softer top-line environment was a net positive and looks to have structurally reset the cost base going forward. CHL achieved positive EBITDA of A$0.3m for the full year on revenue of ~A$39m (-7% on pcp). While ANZ is showing some early signs of recovery (future bookings having risen to a degree), Europe remains a drag. Our DCF/multiples derived valuation and price target remains at A$0.70, and we retain our BUY recommendation.

FY26 result: Dreaming of larger jackpots

Jumbo Interactive
3:27pm
August 28, 2026
Jumbo Interactive (JIN) delivered underlying EBITDA of $85.2m (+25%) and NPATA of $50.6m (+20%), landing above the top of the July pre-release, despite a second consecutive year of historically weak jackpots in Australia. Despite this, the stock closed 3% lower on the day, likely reflecting the uncertainty around Brightstar and FY27 guidance that sat below market expectations in parts, which we regard as conservative. International (Managed Services + Prize Draws) is scaling well, contributing $30.3m vs $7.0m in FY25, while Australia fell 10% on continued large jackpot softness. Following the result, our FY27-28F EPSA estimates reduce 2-4%, and we forecast JIN to return to a net cash position by FY29. We retain a BUY recommendation, with a revised target price of $9.81 (was $10.25).

News & insights

See how global share markets performed in July 2026, from US tech gains to Asian and Australian market strength. Read Scott Fraser's update
Read more
While US employment has barely moved, GDP grew 2.1% over the year to June. We look at how a surge in data centre investment, spanning equipment and intellectual property, is powering growth and lifting productivity even as job creation stalls.
Read more
Discover why Australian interest rates still have further to climb than the US, and what the rate gap could mean for your borrowing and investments.
Read more